<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="mccune-albright" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">mccune-albright</book-part-id>
      <title-group>
        <title>Fibrous Dysplasia/McCune-Albright Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonym: FD/MAS</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Boyce</surname>
            <given-names>Alison M</given-names>
          </name>
          <degrees>MD</degrees>
          <email>boyceam@mail.nih.gov</email>
          <aff>Skeletal Clinical Studies Unit<break/>Craniofacial and Skeletal Diseases Branch<break/>National Institute of Dental and Craniofacial Research<break/>National Institutes of Health<break/>Bethesda, Maryland<break/>Division of Endocrinology and Diabetes<break/>Children&#x02019;s National Health System<break/>Washington, DC<break/>Bone Health Program<break/>Division of Orthopaedics and Sports Medicine<break/>Children&#x02019;s National Health System<break/>Washington, DC</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Collins</surname>
            <given-names>Michael T</given-names>
          </name>
          <degrees>MD</degrees>
          <email>mcollins@dir.nidcr.nih.gov</email>
          <aff>Chief, Skeletal Clinical Studies Unit<break/>Craniofacial and Skeletal Diseases Branch<break/>National Institute of Dental and Craniofacial Research<break/>National Institutes of Health<break/>Bethesda, Maryland</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2015-02-26" date-type="created">
          <day>26</day>
          <month>2</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="feingold" document-type="chapter">Feingold Syndrome 1</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="fhs" document-type="chapter">Floating-Harbor Syndrome</related-object>
      <abstract id="mccune-albright.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS), the result of an early embryonic postzygotic somatic activating mutation of <italic toggle="yes">GNAS</italic> (encoding the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;), is characterized by involvement of the skin, skeleton, and certain endocrine organs. However, because G<sub>s</sub>&#x003b1; signaling is ubiquitous additional tissues may be affected. </p>
          <p>Caf&#x000e9;-au-lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. Fibrous dysplasia (FD), which can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton, can range from an isolated, asymptomatic monostotic lesion discovered incidentally to a severe disabling polyostotic disease involving practically the entire skeleton and leading to progressive scoliosis, facial deformity, and loss of mobility, vision, and/or hearing. Endocrinopathies include: </p>
          <list list-type="bullet">
            <list-item>
              <p>Gonadotropin-independent precocious puberty resulting from recurrent ovarian cysts in girls and autonomous testosterone production in boys;</p>
            </list-item>
            <list-item>
              <p>Testicular lesions with or without associated gonadotropin-independent precocious puberty;</p>
            </list-item>
            <list-item>
              <p>Thyroid lesions with or without non-autoimmune hyperthyroidism; </p>
            </list-item>
            <list-item>
              <p>Growth hormone excess; </p>
            </list-item>
            <list-item>
              <p>FGF23-mediated phosphate wasting with or without hypophosphatemia in association with fibrous dysplasia; and </p>
            </list-item>
            <list-item>
              <p>Neonatal hypercortisolism. </p>
            </list-item>
          </list>
          <p>The prognosis for individuals with FD/MAS is based on disease location and severity.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>In most individuals the diagnosis of FD/MAS is based on the finding of two or more typical clinical features. In individuals whose only clinical finding is monostotic fibrous dysplasia, identification of a somatic activating mutation of <italic toggle="yes">GNAS</italic> is required to establish the diagnosis. Mutation detection depends on the level of mosaicism in the tissue and the sensitivity of the technique. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Management is most effectively accomplished by a multidisciplinary team of specialists. </p>
          <list list-type="bullet">
            <list-item>
              <p>FD. No medical therapies are available; management focuses on optimizing function and minimizing morbidity related to fractures and deformity (including scoliosis). </p>
            </list-item>
            <list-item>
              <p>Precocious puberty. Treatment prevents bone age advancement and compromise of adult height. For girls, options include the aromatase inhibitor letrozole and/or the estrogen receptor modulator tamoxifen; for boys, treatment options are less well established.</p>
            </list-item>
            <list-item>
              <p>Thyroid disease. Methimazole effectively manages hyperthyroidism; however, because hyperthyroidism is persistent, thyroidectomy is common. </p>
            </list-item>
            <list-item>
              <p>Growth hormone excess. Medical therapy is the preferred first-line treatment; options include (alone or in combination) octreotide and the growth hormone receptor antagonist pegvisomant.</p>
            </list-item>
            <list-item>
              <p>Hypercortisolism. Treatment varies by the presentation of neonatal Cushing syndrome. </p>
            </list-item>
          </list>
          <p><italic toggle="yes">Surveillance:</italic>
</p>
          <list list-type="bullet">
            <list-item>
              <p>In all persons with FD/MAS, monitor: </p>
              <list list-type="bullet">
                <list-item>
                  <p>Infants for clinical signs of hypercortisolism; </p>
                </list-item>
                <list-item>
                  <p>Children for growth acceleration and other clinical signs of precocious puberty and/or growth hormone excess; thyroid function tests routinely in children age &#x0003c;5 years; </p>
                </list-item>
                <list-item>
                  <p>Males for testicular lesions with physical examination and testicular ultrasound.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In persons with FD, periodic radiographs to monitor existing FD and development of new lesions; phosphorus levels to monitor for the development of hypophosphatemia. </p>
              <list list-type="bullet">
                <list-item>
                  <p>Craniofacial FD: yearly vision and hearing evaluations; periodic skull CT.</p>
                </list-item>
                <list-item>
                  <p>Spine FD: close monitoring for progressive scoliosis. </p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In children with thyroid abnormalities on ultrasound examination but normal thyroid function, monitor thyroid function periodically. </p>
            </list-item>
          </list>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Contact sports and other high-risk activities (when skeletal involvement is significant); prophylactic optic nerve decompression (in patients with craniofacial FD); surgical removal of ovarian cysts; radiation therapy for treatment of FD; risk factors for malignancy (e.g., radiation exposure). </p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>FD/MAS is not inherited. No parent of a child with FD/MAS has been demonstrated to have any significant, distinctive manifestations of the disorder. The risk to sibs is expected to be the same as in the general population. There are no verified instances of vertical transmission of FD/MAS.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="mccune-albright.Diagnosis">
        <title>Diagnosis</title>
        <sec id="mccune-albright.Establishing_the_Diagnos">
          <title>Establishing the Diagnosis </title>
          <p>The diagnosis of fibrous dysplasia/McCune-Albright syndrome (FD/MAS) can be established in individuals who have two or more typical clinical features of MAS. In individuals whose only clinical finding is monostotic fibrous dysplasia, identification of a <italic toggle="yes">GNAS</italic> somatic activating mutation is required to establish the diagnosis. </p>
          <p>Note that the presence of any features of FD/MAS should prompt more detailed clinical evaluation for additional manifestations. </p>
          <sec id="mccune-albright.Clinical_Findings">
            <title>Clinical Findings </title>
            <p>The diagnosis is established in individuals with two or more of the following features:</p>
            <list list-type="bullet">
              <list-item>
                <p>Caf&#x000e9;-au-lait skin macules with characteristic features, including:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Jagged, irregular borders, often referred to as resembling the &#x02018;coast of Maine&#x02019; (in contrast to the smooth-bordered &#x02018;coast of California&#x02019; lesions seen in <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">neurofibromatosis type 1</related-object>);</p>
                  </list-item>
                  <list-item>
                    <p>Distribution showing an association with (&#x0201c;respecting&#x0201d;) the midline of the body and following the developmental lines of Blaschko, which reflect patterns of embryonic cell migration (<xref ref-type="fig" rid="mccune-albright.F1">Figure 1</xref>).</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Polyostotic fibrous dysplasia (i.e., involvement of &#x0003e;1 bone) or <italic toggle="yes">GNAS</italic> mutation-proven monostotic fibrous dysplasia (i.e., involvement of a single bone) (see <xref ref-type="sec" rid="mccune-albright.Molecular_Genetic_Testin">Molecular Genetic Testing</xref>). As with skin, fibrous dysplasia demonstrates a mosaic pattern: it can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton. Fibrous dysplasia can range from an isolated, asymptomatic monostotic lesion discovered incidentally to a severe disabling polyostotic disease involving practically the entire skeleton and leading to loss of vision, hearing, and/or mobility.The radiographic appearance of fibrous dysplasia varies according to location. </p>
                <list list-type="bullet">
                  <list-item>
                    <p>Radiographs of the appendicular skeleton show expansive lesions with endosteal scalloping, thinning of the cortex, and a "ground glass" appearance (<xref ref-type="fig" rid="mccune-albright.F2">Figure 2A</xref>). </p>
                  </list-item>
                  <list-item>
                    <p>Fibrous dysplasia in the craniofacial skeleton is typically expansile and appears sclerotic on x-ray, but demonstrates a typical &#x0201c;ground glass&#x0201d; appearance on computed tomography (<xref ref-type="fig" rid="mccune-albright.F2">Figure 2C</xref>). </p>
                  </list-item>
                  <list-item>
                    <p>With aging, fibrous dysplasia lesions in the appendicular skeleton tend to become sclerotic on radiographs and craniofacial fibrous dysplasia lesions develop a &#x0201c;cystic&#x0201d; appearance (<xref ref-type="fig" rid="mccune-albright.F2">Figure 2D</xref>). </p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Any of the following primary endocrinopathies:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Gonadotropin-independent precocious puberty resulting from recurrent ovarian cysts in girls and autonomous testosterone production in boys (<xref ref-type="fig" rid="mccune-albright.F3">Figure 3A</xref> and <xref ref-type="fig" rid="mccune-albright.F3">Figure 3B</xref>)</p>
                  </list-item>
                  <list-item>
                    <p>Testicular lesions including Leydig and/or Sertoli cell hyperplasia with characteristic ultrasonographic features, with or without associated gonadotropin-independent precocious puberty (<xref ref-type="fig" rid="mccune-albright.F3">Figure 3B</xref>) </p>
                  </list-item>
                  <list-item>
                    <p>Thyroid lesions with characteristic ultrasonographic features, with or without non-autoimmune hyperthyroidism </p>
                  </list-item>
                  <list-item>
                    <p>Growth hormone excess</p>
                  </list-item>
                  <list-item>
                    <p>FGF23-mediated phosphate wasting with or without hypophosphatemia in association with fibrous dysplasia</p>
                  </list-item>
                  <list-item>
                    <p>Neonatal hypercortisolism </p>
                  </list-item>
                </list>
              </list-item>
            </list>
          </sec>
          <sec id="mccune-albright.Molecular_Genetic_Testin">
            <title>Molecular Genetic Testing</title>
            <p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS), a sporadically occurring disorder, results from an early embryonic postzygotic somatic activating (gain-of-function) mutation of <italic toggle="yes">GNAS</italic> (encoding the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;).</p>
            <p>Somatic <italic toggle="yes">GNAS</italic> missense mutations in individuals with FD/MAS are known to occur at only one of two amino acid residues: Arg201 (&#x0003e;95% of mutations) [<xref ref-type="bibr" rid="mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</xref>] or Gln227 (&#x0003c;5%) [<xref ref-type="bibr" rid="mccune-albright.REF.idowu.2007.691">Idowu et al 2007</xref>] (see <xref ref-type="sec" rid="mccune-albright.Molecular_Genetics">Molecular Genetics</xref>, <bold>Pathogenic allelic variants</bold>). </p>
            <p>Mutation detection depends on the level of mosaicism in the tissue and the sensitivity of the technique. </p>
            <list list-type="bullet">
              <list-item>
                <p>By standard PCR, mosaic somatic mutation at <italic toggle="yes">GNAS</italic> Arg201 (see <xref ref-type="table" rid="mccune-albright.T.gnas_somatic_variants">Table 2</xref>) was detected in affected tissues in up to 90% of individuals with two or three features of MAS and in leukocytes in as few as 8% of individuals with only one feature of MAS [<xref ref-type="bibr" rid="mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</xref>]. Of note, detection frequency of an Arg201 variant was highest in endocrine organs and lowest in affected skin specimens [<xref ref-type="bibr" rid="mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</xref>]. </p>
              </list-item>
              <list-item>
                <p>When modified primers (peptide nucleic acid) [<xref ref-type="bibr" rid="mccune-albright.REF.bianco.2000.120">Bianco et al 2000</xref>] and next-generation sequencing [<xref ref-type="bibr" rid="mccune-albright.REF.narumi.2013.e60525">Narumi et al 2013</xref>] technologies are combined [<xref ref-type="bibr" rid="mccune-albright.REF.narumi.2013.e60525">Narumi et al 2013</xref>], an Arg201 variant can be detected in virtually all affected tissues and in leukocytes of up to 75% of individuals. </p>
              </list-item>
            </list>
            <p>Note: G<sub>s</sub>&#x003b1; is expressed in nearly all tissues from both maternal and paternal <italic toggle="yes">GNAS</italic> alleles. However, <italic toggle="yes">GNAS</italic> is a complex locus where alternative transcripts and additional phenotypes may result from <italic toggle="yes">GNAS</italic> imprinting (see <xref ref-type="sec" rid="mccune-albright.Genetically_Related_Alle">Genetically Related Disorders</xref> and <xref ref-type="sec" rid="mccune-albright.Molecular_Genetics">Molecular Genetics</xref>). </p>
            <table-wrap id="mccune-albright.T.summary_of_molecular_g" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in McCune-Albright Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutations Detected</th>
                    <th id="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands in whom a Pathogenic Variant is Detected&#x000a0;<sup>2</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">GNAS</italic>
                    </td>
                    <td headers="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted sequence analysis of exons 8 and 9&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="table" rid="mccune-albright.T.gnas_somatic_variants">p.Arg201His</xref>, <xref ref-type="table" rid="mccune-albright.T.gnas_somatic_variants">p.Arg201Cys</xref>&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_mccune-albright.T.summary_of_molecular_g_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">8%-90%&#x000a0;<sup>5</sup><break/>75%-100%&#x000a0;<sup>6</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="mccune-albright.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="mccune-albright" object-id="mccune-albright.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="mccune-albright.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene. </p>
                </fn>
                <fn id="mccune-albright.TF.1.2">
                  <label>2. </label>
                  <p>Variability due to type of tissue available for testing and number of features of MAS [<xref ref-type="bibr" rid="mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</xref>]. </p>
                </fn>
                <fn id="mccune-albright.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="mccune-albright.TF.1.4">
                  <label>4. </label>
                  <p>Testing typically detects an p.Arg201His or p.Arg201Cys variant. Rarely other amino acid substitutions can be seen at the exon 8 Arg201 position. Rarely amino acid substitutions can be seen at the exon 9 Gln227 position. Variants at Arg201 and Gln227 are detailed in <xref ref-type="sec" rid="mccune-albright.Molecular_Genetics">Molecular Genetics</xref>.</p>
                </fn>
                <fn id="mccune-albright.TF.1.5">
                  <label>5. </label>
                  <p>
                    <xref ref-type="bibr" rid="mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al [2004]</xref>
                  </p>
                </fn>
                <fn id="mccune-albright.TF.1.6">
                  <label>6. </label>
                  <p><xref ref-type="bibr" rid="mccune-albright.REF.narumi.2013.e60525">Narumi et al [2013]</xref> detected Arg201 mutations in 100% of affected tissues and 75% of blood samples by a PNA-NGS technique. </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="mccune-albright.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="mccune-albright.Natural_History">
          <title>Clinical Description</title>
          <p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) results from mosaic somatic activating mutations in <italic toggle="yes">GNAS</italic> which encodes the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;. Affected tissues can include those derived from ectoderm, mesoderm and endoderm, and commonly include skin, skeleton, and certain endocrine organs. However, because G<sub>s</sub>&#x003b1; signaling is present in virtually every tissue additional tissues may be affected. </p>
          <p>The phenotypic spectrum of FD/MAS ranges from asymptomatic incidental findings to neonatal lethality. There is a high degree of variability between individuals, both in the number of affected tissues and the degree to which they are affected. Disease manifestations depend on the time during embryogenesis that the somatic mutation occurred, the tissue involved, and the role of G<sub>s</sub>&#x003b1; in the affected tissue. Mutations occurring early in development lead to widespread disease, while those occurring later in development lead to limited disease. </p>
          <p><bold>Pigmented macules</bold><italic toggle="yes">.</italic> Caf&#x000e9;-au-lait skin macules are common and are usually the first manifestation of the disease, apparent at or shortly after birth. There is no correlation with the size of the skin lesions and the extent of disease, nor is there a correlation between the distribution of skin lesions and the location of fibrous dysplasia. </p>
          <p><bold>Fibrous dysplasia of bone.</bold> As with skin, fibrous dysplasia demonstrates a mosaic pattern: it can involve any part and combination of the craniofacial, axial, and/or appendicular skeleton. The bones most commonly involved are the skull base and proximal femurs [<xref ref-type="bibr" rid="mccune-albright.REF.kelly.2008.57">Kelly et al 2008</xref>]. While there is generally a central to peripheral gradient, any combination of involved bones is possible. </p>
          <p>Fibrous dysplasia can manifest along a wide spectrum from an isolated, asymptomatic monostotic lesion discovered incidentally, to severe disabling polyostotic disease involving practically the entire skeleton and leading to loss of vision, hearing, and/or mobility. </p>
          <p>Individual bone lesions typically manifest during the first few years of life and expand during childhood. The vast majority of clinically significant bone lesions are detectable by age 10 years, with few new and almost no clinically significant bone lesions appearing after age 15 years [<xref ref-type="bibr" rid="mccune-albright.REF.hart.2007.1468">Hart et al 2007</xref>]. In adulthood fibrous dysplasia lesions typically become less active, likely related to apoptosis of mutation-bearing cells [<xref ref-type="bibr" rid="mccune-albright.REF.kuznetsov.2008.1731">Kuznetsov et al 2008</xref>]. </p>
          <p>The clinical presentation and course of fibrous dysplasia depends on the location and extent of the affected skeleton. </p>
          <p>Children with fibrous dysplasia in the appendicular skeleton typically present with a limp, pain, and/or pathologic fractures. Recurrent fractures and progressive deformity may lead to difficulties with ambulation and loss of mobility. </p>
          <p>In the craniofacial region, fibrous dysplasia may present as a painless &#x0201c;lump&#x0201d; or facial asymmetry. Expansion of craniofacial lesions may lead to progressive facial deformity (<xref ref-type="fig" rid="mccune-albright.F2">Figure 2B</xref>), and in rare cases (usually in association with growth hormone excess) loss of vision and/or hearing due to compromise of the optic nerves and/or external auditory canals [<xref ref-type="bibr" rid="mccune-albright.REF.cutler.2006.1011">Cutler et al 2006</xref>]. </p>
          <p>Fibrous dysplasia involving the vertebrae is common, and may lead to scoliosis, which in rare instances may be severe, progressive, and even lethal [<xref ref-type="bibr" rid="mccune-albright.REF.leet.2004b.531">Leet et al 2004b</xref>]. Untreated, progressive scoliosis is one of the few features of fibrous dysplasia that can lead to early morbidity. </p>
          <p>Bone pain is a common complication of fibrous dysplasia [<xref ref-type="bibr" rid="mccune-albright.REF.kelly.2008.57">Kelly et al 2008</xref>]. Although bone pain may present at any age, it is common for bone pain to be absent in childhood, occur in adolescence, and progress into adulthood.</p>
          <p>Malignant transformation of FD lesions is a rare complication. Many instances of malignant transformation were reported in association with previous radiation treatment [<xref ref-type="bibr" rid="mccune-albright.REF.ruggieri.1994.1411">Ruggieri et al 1994</xref>]. Growth hormone excess may be a predisposing factor [<xref ref-type="bibr" rid="mccune-albright.REF.salenave.2014.1955">Salenave et al 2014</xref>]</p>
          <p>Fibrous dysplasia tissue produces excess amounts of the phosphate-regulating hormone fibroblast growth factor-23 (FGF23), leading to loss of phosphate in the urine [<xref ref-type="bibr" rid="mccune-albright.REF.riminucci.2003.683">Riminucci et al 2003</xref>]. Patients with frank hypophosphatemia may develop rickets/osteomalacia, increased fractures, and bone pain [<xref ref-type="bibr" rid="mccune-albright.REF.leet.2004a.571">Leet et al 2004a</xref>].</p>
          <p><bold>Endocrinopathies</bold> can include any of the following:</p>
          <p><bold>Precocious puberty.</bold> Precocious puberty is common in girls with FD/MAS (~85%), and is often the presenting feature. Recurrent ovarian cysts lead to intermittent estrogen production resulting in breast development, growth acceleration, and vaginal bleeding; during the intervals between cyst formation, breast tissue typically regresses and estrogen levels fall to prepubertal levels<bold>.</bold> Ovarian cysts typically continue into adulthood, leading to irregular menses. This has the potential to interrupt ovulatory cycles, which may increase the time to conception in adult women. Ovarian torsion has been seen rarely in women with large and persistent cysts [<xref ref-type="bibr" rid="mccune-albright.REF.clark.2000.204">Clark et al 2000</xref>]. </p>
          <p>Precocious puberty is less common in males with FD/MAS (~10-15%). In affected boys, autonomous testosterone production leads to progressive pubertal development including growth acceleration, pubic and axillary hair, acne, and aggressive and/or inappropriately sexual behavior. </p>
          <p>In both girls and boys, prolonged autonomous sex steroid production typically leads to activation of the hypothalamic-pituitary axis and the development of central precocious puberty. </p>
          <p>The effects of autonomous sex steroid production on pituitary-gonadal function and fertility in adults are not well-characterized. Women with FD/MAS may have recurrent cysts leading to irregular menses in adulthood [<xref ref-type="bibr" rid="mccune-albright.REF.lala.2007.423">Lala et al 2007</xref>]. While many women in the NIH cohort have achieved successful pregnancies [Authors, personal observation], it is possible that interruption of ovulatory cycles could decrease fertility and increase the time to conception. </p>
          <p><bold>Testicular abnormalities.</bold> Testicular abnormalities are seen in the majority of males with MAS (~85%), and typically manifest as unilateral or bilateral macro-orchidism [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2012.e1782">Boyce et al 2012</xref>]. Ultrasound examination demonstrates discrete hyper- and hypoechoic lesions and microlithiasis, corresponding to areas of Leydig and/or Sertoli cell hyperplasia (<xref ref-type="fig" rid="mccune-albright.F3">Figure 3B</xref>). </p>
          <p>The potential for malignant transformation of testicular lesions is unknown, but appears to be low [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2012.e1782">Boyce et al 2012</xref>].</p>
          <p><bold>Thyroid disease.</bold> Thyroid involvement in FD/MAS is common. Approximately one-third of individuals with FD/MAS have hyperthyroidism, and a larger proportion (54%) have ultrasound findings consistent with thyroid involvement, including mixed cystic and solid lesions interspersed with areas of normal-appearing tissue (<xref ref-type="fig" rid="mccune-albright.F3">Figure 3C&#x00026;D</xref>) [<xref ref-type="bibr" rid="mccune-albright.REF.celi.2008.2383">Celi et al 2008</xref>]. </p>
          <p>Hyperthyroidism in FD/MAS results from both increased hormone production, as well as increased conversion of thyroxine (T4) to triiodothyronine (T3) [<xref ref-type="bibr" rid="mccune-albright.REF.celi.2008.2383">Celi et al 2008</xref>]. Hyperthyroidism is typically mild to moderate, but may be severe, and if undetected can lead to thyroid storm during anesthetic induction for surgery [<xref ref-type="bibr" rid="mccune-albright.REF.lawless.1992.1099">Lawless et al 1992</xref>]. Uncontrolled hyperthyroidism may lead to bone age advancement, elevated bone turnover, and fractures. </p>
          <p>Malignant transformation of affected thyroid tissue has rarely been reported [<xref ref-type="bibr" rid="mccune-albright.REF.collins.2003.4413">Collins et al 2003</xref>]. </p>
          <p><bold>FGF23-mediated phosphate wasting.</bold> In the majority of individuals with FD increased production of the phosphaturic hormone FGF23 in FD tissue results in a renal tubulopathy with some degree of phosphate wasting [<xref ref-type="bibr" rid="mccune-albright.REF.collins.2001.806">Collins et al 2001</xref>]. However, frank hypophosphatemia in persons with FD is infrequent, in part due to alterations in FGF23 processing that takes place in FD tissue and results in increased cleavage of FGF23 to its inactive fragments [<xref ref-type="bibr" rid="mccune-albright.REF.bhattacharyya.2012.1132">Bhattacharyya et al 2012</xref>]. The degree of FGF23 overproduction in FD correlates with disease severity and skeletal burden; thus, frank hypophosphatemia is only seen in individuals with a substantial FD burden. In contrast to most other features of FD/MAS, hypophosphatemia may wax and wane over the course of a person&#x02019;s lifetime, and become more severe during periods of rapid skeletal growth. Hypophosphatemia may resolve as persons with FD become older, likely reflecting the intrinsic changes in FD that occur with age, including a decline in the number of mutated stromal cells and the tendency of histologic features to improve over time [<xref ref-type="bibr" rid="mccune-albright.REF.kuznetsov.2008.1731">Kuznetsov et al 2008</xref>].</p>
          <p>Clinical sequelae of FGF23-mediated hypophosphatemia in FD include earlier onset, increased risk of fractures, and FD-related bone pain [<xref ref-type="bibr" rid="mccune-albright.REF.leet.2004a.571">Leet et al 2004a</xref>]. </p>
          <p><bold>Growth hormone excess.</bold> Approximately 10%-15% of individuals with FD/MAS harbor <italic toggle="yes">GNAS</italic> mutations in the anterior pituitary that can lead to autonomous growth hormone production, typically accompanied by hyperprolactinemia [<xref ref-type="bibr" rid="mccune-albright.REF.salenave.2014.1955">Salenave et al 2014</xref>]. </p>
          <p>Affected individuals typically present with linear growth acceleration, and may develop features of acromegaly. Clinically, growth hormone excess must be distinguished from precocious puberty, which also presents with growth acceleration. </p>
          <p>Untreated growth hormone excess is associated with expansion of craniofacial fibrous dysplasia, leading to macrocephaly and increased risk of vision loss [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2013.e126">Boyce et al 2013</xref>] (<xref ref-type="fig" rid="mccune-albright.F2">Figure 2B</xref>).</p>
          <p><bold>Hypercortisolism.</bold> Infants with FD/MAS may rarely present with Cushing syndrome due to excess cortisol production from the fetal adrenal gland [<xref ref-type="bibr" rid="mccune-albright.REF.brown.2010.1508">Brown et al 2010</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.carney.2011.1311">Carney et al 2011</xref>]. Clinical symptoms typically develop in the neonatal period, and may be severe, leading to critical illness and death. Spontaneous regression has been reported in approximately half of survivors, presumably related to fetal adrenal involution. </p>
          <p><bold>Less common manifestations</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Liver.</bold> Hepatitis may be pronounced in infants, and generally wanes with age to a mild persistent form [<xref ref-type="bibr" rid="mccune-albright.REF.gaujoux.2014.e97">Gaujoux et al 2014</xref>]. Hepatic adenomas have also been reported [<xref ref-type="bibr" rid="mccune-albright.REF.silva.2000.154">Silva et al 2000</xref>]. Liver failure or functional defects associated with FD/MAS have not been reported. </p>
            </list-item>
            <list-item>
              <p><bold>Gastrointestinal.</bold> Gastroesophageal reflux manifests in childhood and may be severe. Gastrointestinal polyps have also been observed [<xref ref-type="bibr" rid="mccune-albright.REF.zacharin.2011.458">Zacharin et al 2011</xref>]. </p>
            </list-item>
            <list-item>
              <p><bold>Pancreas.</bold> Pancreatic complications have included pancreatitis and intraductal papillary mucinous neoplasms [<xref ref-type="bibr" rid="mccune-albright.REF.silva.2000.154">Silva et al 2000</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.gaujoux.2014.e97">Gaujoux et al 2014</xref>]. Pancreatic cancer associated with FD/MAS has not been reported.</p>
            </list-item>
            <list-item>
              <p><bold>Myxomas.</bold> Intramuscular myxomas are benign, usually asymptomatic, and often found incidentally. The association of intramuscular myxomas with FD/MAS has been termed Mazabraud syndrome [<xref ref-type="bibr" rid="mccune-albright.REF.zoccali.2009.605">Zoccali et al 2009</xref>]. </p>
            </list-item>
            <list-item>
              <p><bold>Malignancies.</bold> Cancers reported in association with FD/MAS include bone [<xref ref-type="bibr" rid="mccune-albright.REF.ruggieri.1994.1411">Ruggieri et al 1994</xref>], thyroid [<xref ref-type="bibr" rid="mccune-albright.REF.collins.2003.4413">Collins et al 2003</xref>], testicular [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2012.e1782">Boyce et al 2012</xref>], and breast [<xref ref-type="bibr" rid="mccune-albright.REF.tanabeu.1998.175">Tanabeu et al 1998</xref>]. In some instances (see for example, <xref ref-type="bibr" rid="mccune-albright.REF.collins.2003.4413">Collins et al [2003]</xref>), somatic activating <italic toggle="yes">GNAS</italic> mutations have been found in the cancer tissue but not in adjacent normal tissue, supporting a causative role. Likewise, the FD/MAS-associated activating <italic toggle="yes">GNAS</italic> mutations at residues Arg201 and Gln227 (collectively referred to as the <italic toggle="yes">gsp</italic> oncogene) have been reported in nonsyndromic benign [<xref ref-type="bibr" rid="mccune-albright.REF.landis.1989.692">Landis et al 1989</xref>] and malignant [<xref ref-type="bibr" rid="mccune-albright.REF.wood.2007.1108">Wood et al 2007</xref>] tumors. Other features of FD/MAS such as precocious puberty and growth hormone excess may also contribute to an increased risk of cancer. </p>
            </list-item>
          </list>
          <p><bold>Health-related quality of life.</bold> Social and emotional functioning was found to be normal in one large series, with individuals reporting high levels of self-esteem and social function [<xref ref-type="bibr" rid="mccune-albright.REF.kelly.2005.388">Kelly et al 2005</xref>]. </p>
          <p><bold>Prognosis.</bold> The prognosis for individuals with FD/MAS is based on disease location and severity. </p>
          <p>Medical therapies can ameliorate or control endocrine disease in most individuals (see <xref ref-type="sec" rid="mccune-albright.Management">Management</xref>). </p>
          <p>Fibrous dysplasia is progressive throughout childhood and adolescence, and typically plateaus in middle and late adulthood. Small amounts of fibrous dysplasia may cause few or no symptoms; however, individuals with extensive bone disease may experience significant sequelae including loss of mobility, progressive scoliosis, facial deformity, and loss of vision and/or hearing. </p>
        </sec>
        <sec id="mccune-albright.GenotypePhenotype_Correl">
          <title>Genotype-Phenotype Correlations</title>
          <p>There are no known genotype-phenotype correlations. </p>
          <p>To date only activating <italic toggle="yes">GNAS</italic> somatic mutations at residues Arg201 and Gln227 have been identified in individuals with FD/MAS. </p>
          <p>Disease severity is likely correlated with the degree of mosaicism and the tissues that are affected.</p>
        </sec>
        <sec id="mccune-albright.Prevalence">
          <title>Prevalence </title>
          <p>FD/MAS is rare. While reliable data of prevalence are not available, estimates range between 1:100,000 and 1:1,000,000. </p>
          <p>In contrast, fibrous dysplasia (particularly the monostotic form) is not rare, and has been estimated to account for as much as 7% of all benign bone tumors. </p>
          <p>FD/MAS affects both sexes and does not have a predilection for any particular populations.</p>
        </sec>
      </sec>
      <sec id="mccune-albright.Genetically_Related_Alle">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>In contrast to somatic activating (gain-of-function) mutations at specific <italic toggle="yes">GNAS</italic> residues resulting in FD/MAS, germline inactivating (loss-of-function) <italic toggle="yes">GNAS</italic> mutations are associated with multiple phenotypes. Furthermore, since <italic toggle="yes">GNAS</italic> is an imprinted gene, the phenotype associated with germline inactivating mutations depends on the parent of origin (maternal vs paternal) of the mutant allele and the degree of imprinting that occurs in a given tissue.&#x000a0;</p>
        <p>The following phenotypes with germline inactivating <italic toggle="yes">GNAS</italic> mutations have been described:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pseudopseudohypoparathyroidism</bold> (PPHP, Albright hereditary osteodystrophy without hormone resistance; OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/612463">612463</ext-link>) is characterized by short stature, shortened fourth and fifth metacarpals without endocrine abnormalities, a normal cellular cAMP response to parathyroid hormone (PTH) infusion, and decreased erythrocyte G<sub>s</sub>&#x003b1; activity. It is caused by an inactivating mutation of the paternal <italic toggle="yes">GNAS</italic> allele resulting in expression of the protein product G<sub>s</sub>&#x003b1; only from the maternal allele [<xref ref-type="bibr" rid="mccune-albright.REF.weinstein.1990.8287">Weinstein et al 1990</xref>]. </p>
          </list-item>
          <list-item>
            <p><bold>Pseudohypoparathyroidism 1A</bold> (Albright hereditary osteodystrophy with multiple hormone resistance; OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/103580">103580</ext-link>) is characterized by short stature, shortened fourth and fifth metacarpals, resistance to PTH (with hypocalcemia, hyperphosphatemia, and increased serum PTH concentration), as well as variable resistance to other hormones, including thyroid-stimulating hormone (TSH) and gonadotropins (LH and FSH) and growth hormone-releasing hormone. It is caused by an inactivating mutation of the maternal <italic toggle="yes">GNAS</italic> allele resulting in expression of the protein product G<sub>s</sub>&#x003b1; only from the paternal allele [<xref ref-type="bibr" rid="mccune-albright.REF.davies.1993.101">Davies &#x00026; Hughes 1993</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.levine.2012.443">Levine 2012</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Pseudohypoparathyroidism IB</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/603233">603233</ext-link>) is characterized by isolated renal resistance to PTH manifest by increased serum PTH concentration, hypocalcemia, hyperphosphatemia, and decreased excretion of urinary cAMP in response to exogenous PTH. Note that G<sub>s</sub>&#x003b1; activity in erythrocytes is normal because the defect is restricted to renal proximaltubule cells. The physical characteristics of Albright hereditary osteodystrophy are usually absent. Although no other endocrine abnormalities are typically observed, resistance to thyroid-stimulating hormone (TSH) has been reported. It is caused by deletion of the regulatory differentially methylated region of the <italic toggle="yes">GNAS</italic> locus [<xref ref-type="bibr" rid="mccune-albright.REF.j_ppner.1998.11798">J&#x000fc;ppner et al 1998</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.mantovani.2011.3020">Mantovani 2011</xref>]. </p>
          </list-item>
          <list-item>
            <p><bold>Progressive osseous heteroplasia</bold> (POH; OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/166350">166350</ext-link>) is characterized by dermal ossification that begins in infancy and can progress to extensive bone formation in deep muscle and fascia. Hormone resistance is not observed. The cause is believed to be an inactivating <italic toggle="yes">GNAS</italic> mutation of the paternal allele, as in PPHP [<xref ref-type="bibr" rid="mccune-albright.REF.shore.2002.99">Shore et al 2002</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.pignolo.2015.37">Pignolo et al 2015</xref>]. An explanation for the difference in phenotype between POH and PPHP is lacking.</p>
          </list-item>
        </list>
      </sec>
      <sec id="mccune-albright.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter"><bold>Neurofibromatosis type 1</bold></related-object>
<bold>(NF1)</bold> and FD/MAS have several overlapping features, including caf&#x000e9;-au-lait macules and skeletal abnormalities. Skin findings in NF1 include six or more caf&#x000e9;-au-lait macules, which are generally smooth-bordered (&#x0201c;coast of California&#x0201d;, as opposed to the irregularly-bordered &#x0201c;coast of Maine&#x0201d; lesions seen in FD/MAS). Skeletal features of NF1 include kyphoscoliosis, sphenoid dysplasia, cortical thinning of long bones, and bowing and dysplasia particularly of the tibia which may result in pseudarthroses. Distinct features of NF1 include tumors of the nervous system such as neurofibromas and optic gliomas, pigmented iris hamartomas, and axillary freckling. NF1 is caused by mutation of <italic toggle="yes">NF1</italic> and is inherited in an autosomal dominant manner. </p>
        <p><bold>Cutaneous-skeletal hypophosphatemia syndrome</bold> is a mosaic disorder resulting from somatic activating mutations in <italic toggle="yes">HRAS</italic> and <italic toggle="yes">NRAS</italic> [<xref ref-type="bibr" rid="mccune-albright.REF.lim.2014.397">Lim et al 2014</xref>]<italic toggle="yes">.</italic> Affected individuals develop cutaneous lesions (epidermal and large congenital melanocytic nevi) following a mosaic distribution, a mosaic skeletal dysplasia, overproduction of FGF23 resulting in rickets/osteomalacia, and variable other associated anomalies of the eye, brain, and vasculature.</p>
        <p><bold>Fibro-osseous skeletal lesions</bold> may have radiologic and/or histologic features similar to fibrous dysplasia. These lesions are typically solitary, not associated with extraskeletal features, and negative for mutation of <italic toggle="yes">GNAS</italic>.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Giant cell tumors of bone</bold> are acquired lesions which share similar histopathologic features to fibrous dysplasia, including proliferation of bone marrow stromal cells and the presence of multiple multinucleated giant cells. Giant cell tumors are typically benign, but may result in localized bone destruction and rarely metastases.</p>
          </list-item>
          <list-item>
            <p><bold>Ossifying fibromas</bold> are benign lesions typically affecting the mandible and maxillae and presenting with local expansion of a firm, painless mass. Ossifying fibromas are generally more aggressive than craniofacial fibrous dysplasia lesions, and are treated with surgical excision. </p>
          </list-item>
          <list-item>
            <p><bold>Osteofibrous dysplasia</bold> lesions typically occur in children younger than age ten years, and most commonly affect the anterior tibia. Affected children present with painless localized swelling and, in rare cases, with fracture or progressive deformity. Radiographs show a well-circumscribed radiolucent lesion with a characteristic sclerotic rim along the intra-cortical surface. </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cherubism" document-type="chapter"><bold>Cherubism</bold></related-object> is characterized by progressive fibro-osseous lesions of the mandible and maxilla primarily. It typically presents in early childhood with bilateral, symmetric enlargement of the lower face leading to a characteristic, &#x0201c;cherubic&#x0201d; appearance in which the eyes appear to gaze upward because of maxillary involvement. Facial deformity progresses during childhood and early puberty, after which it sometimes spontaneously regresses. In most cases, cherubism arises from heterozygous mutation of <italic toggle="yes">SH3BP2</italic>.</p>
          </list-item>
        </list>
      </sec>
      <sec id="mccune-albright.Management">
        <title>Management</title>
        <p>Note: Linked pdfs included in the Management section are from <xref ref-type="bibr" rid="mccune-albright.REF.boyce.2012">Boyce &#x00026; Collins [2012]</xref>. </p>
        <sec id="mccune-albright.Evaluations_Following_In">
          <title>Evaluations Following Initial Diagnosis </title>
          <p>After the initial diagnosis, all individuals with fibrous dysplasia/McCune-Albright syndrome (FD/MAS) should be evaluated to determine the extent of disease. The authors recommend the following studies:</p>
          <p><bold>Skeleton</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>FD evaluation. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP02.pdf" content-type="local-data">Fibrous Dysplasia Evaluation</inline-supplementary-material> (pdf).</p>
            </list-item>
            <list-item>
              <p>Total body bone scintigraphy to identify and determine the extent of FD [<xref ref-type="bibr" rid="mccune-albright.REF.collins.2005.219">Collins et al 2005</xref>]. The majority of clinically significant skeletal lesions are apparent on bone scan by age five years.</p>
            </list-item>
            <list-item>
              <p>Imaging of areas of FD identified with bone scintigraphy with radiographs (axial and appendicular FD) and/or computed tomography (craniofacial FD) to more clearly evaluate the extent and anatomy of the lesions</p>
            </list-item>
            <list-item>
              <p>Baseline ophthalmologic, otolaryngologic, and audiologic evaluations in persons with craniofacial FD </p>
            </list-item>
          </list>
          <p>
            <bold>Endocrine</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In individuals with clinical signs or a previous history of precocious puberty: biochemical screening, pelvic ultrasound examination (females), and bone age examination. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP04.pdf" content-type="local-data">Gonadal Evaluation in Girls</inline-supplementary-material> (pdf). </p>
            </list-item>
            <list-item>
              <p>Ultrasound examination of the testes (in all males) to evaluate for subclinical disease. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP06.pdf" content-type="local-data">Gonadal Evaluation in Boys</inline-supplementary-material> (pdf).</p>
            </list-item>
            <list-item>
              <p><inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP10.pdf" content-type="local-data">Growth hormone excess evaluation</inline-supplementary-material> (pdf)</p>
            </list-item>
            <list-item>
              <p>A thorough history and physical examination and review of a growth chart (if available) to evaluate for clinical signs of endocrinopathies</p>
            </list-item>
            <list-item>
              <p>Biochemical screening for hyperthyroidism, growth hormone excess (IGF-1 level), and FGF23-mediated hypophosphatemia </p>
            </list-item>
            <list-item>
              <p>Ultrasound examination of the thyroid gland to evaluate for subclinical disease. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP08.pdf" content-type="local-data">Thyroid Evaluation</inline-supplementary-material> (pdf).</p>
            </list-item>
            <list-item>
              <p><inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP14.pdf" content-type="local-data">Adrenal evaluation</inline-supplementary-material> (pdf)</p>
            </list-item>
          </list>
          <p><bold>Less common manifestations.</bold> Consideration should be given to the less common manifestations cited in <xref ref-type="sec" rid="mccune-albright.Natural_History">Clinical Description</xref> with appropriate clinical evaluations and imaging/biochemical studies performed as indicated. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP12.pdf" content-type="local-data">Gastrointestinal Evaluation</inline-supplementary-material> (pdf).</p>
        </sec>
        <sec id="mccune-albright.Treatment_of_Manifestati">
          <title>Treatment of Manifestations</title>
          <p>Management is most effectively accomplished through the input of a multidisciplinary team of specialists including an endocrinologist, orthopedic surgeon, physiatrist, ophthalmologist, audiologist, endocrine surgeon, craniofacial surgeon, and medical geneticist. </p>
          <sec id="mccune-albright.Fibrous_Dysplasia">
            <title>Fibrous Dysplasia</title>
            <p>There are no available medical therapies capable of altering the disease course in fibrous dysplasia. Current management is focused on optimizing function and minimizing morbidity related to fractures and deformity. The primary elements of management include the following. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP03.pdf" content-type="local-data">Fibrous Dysplasia Management</inline-supplementary-material> (pdf): </p>
            <list list-type="bullet">
              <list-item>
                <p>Orthopedic surgery to repair fractures and to prevent and correct deformities. A surgeon experienced in FD should be consulted, as approaches previously considered &#x0201c;standard,&#x0201d; (e.g., curettage, grafting, and external fixation) are frequently ineffective [<xref ref-type="bibr" rid="mccune-albright.REF.stanton.2012.s1">Stanton et al 2012</xref>]. </p>
              </list-item>
              <list-item>
                <p>Diagnosis and treatment of scoliosis is of particular importance, as it may be rapidly progressive and in rare cases may lead to fatal respiratory compromise. For this reason all individuals with spinal FD should be monitored closely by an orthopedic surgeon or physiatrist for possible progression. Surgical fusion has been shown to be effective at stabilizing the spine [<xref ref-type="bibr" rid="mccune-albright.REF.leet.2004b.531">Leet et al 2004b</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.mancini.2009.196">Mancini et al 2009</xref>].</p>
              </list-item>
              <list-item>
                <p>Aneurysmal bone cysts, best detected by MRI, are rapidly expanding fluid-filled lesions that form within preexisting areas of FD. Patients experience acute onset of severe pain, rapidly expanding localized deformity, and rarely &#x02013; when cysts compress the optic nerve &#x02013; sudden loss of vision. Aneurysmal bone cysts thus carry a high risk of morbidity and should be evaluated urgently by a surgeon [<xref ref-type="bibr" rid="mccune-albright.REF.lee.2012.s2">Lee et al 2012</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.manjila.2013">Manjila et al 2013</xref>]. </p>
              </list-item>
              <list-item>
                <p>Prophylactic optic nerve decompression to reduce the risk of vision loss can in fact increase the risk of vision loss and is thus contraindicated [<xref ref-type="bibr" rid="mccune-albright.REF.lee.2002.1670">Lee et al 2002</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.cutler.2006.1011">Cutler et al 2006</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.amit.2011.e25179">Amit et al 2011</xref>].</p>
              </list-item>
              <list-item>
                <p>Physical therapy to optimize function and attenuate loss of mobility is appropriate. Patients with lower-extremity FD in particular may benefit from therapies to address hip girdle weakness, range of motion, and leg length discrepancies [<xref ref-type="bibr" rid="mccune-albright.REF.paul.2014.41">Paul et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p>Intravenous bisphosphonates such as zoledronic acid and pamidronate are usually effective at relieving bone pain. Dosing should be based on symptoms, not on a fixed interval or bone turnover markers. Note: The oral bisphosphonate alendronate has been shown to be ineffective for treatment of bone pain [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2014.4133">Boyce et al 2014</xref>]. </p>
              </list-item>
              <list-item>
                <p>Malignancy should remain a consideration for individuals with acute or rapidly expanding FD lesions, or with atypical radiographic features such as compromise of the bony cortex with an associated soft tissue mass. </p>
              </list-item>
            </list>
          </sec>
          <sec id="mccune-albright.Endocrinopathies">
            <title>Endocrinopathies </title>
            <p><bold>Precocious puberty.</bold> Treatment of precocious puberty is important to prevent bone age advancement and compromise of adult height. </p>
            <p>Effective treatment options for girls include the aromatase inhibitor letrozole [<xref ref-type="bibr" rid="mccune-albright.REF.feuillan.2007.2100">Feuillan et al 2007</xref>] and/or the estrogen receptor modulator tamoxifen [<xref ref-type="bibr" rid="mccune-albright.REF.eugster.2003.60">Eugster et al 2003</xref>]. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP05.pdf" content-type="local-data">Precocious Puberty Management in Girls</inline-supplementary-material> (pdf). The primary clinical endpoints are prevention of growth acceleration and bone age advancement. Most girls will also have a decrease in the number of menstrual bleeding episodes while on treatment. Note: Prophylactic surgical intervention for large and persistent ovarian cysts should be undertaken with extreme caution due to the known risks of recurrent cysts and the potential for decreased ovarian reserve in affected women.</p>
            <p>Given the rarity of precocious puberty in males, treatment options are less well established. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP07.pdf" content-type="local-data">Gonadal Involvement Management in Boys</inline-supplementary-material> (pdf). One strategy includes the combination of an androgen receptor blocker (e.g., spironolactone or flutamide) and an inhibitor of sex steroid synthesis (e.g., letrozole) [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2012.e1782">Boyce et al 2012</xref>].</p>
            <p>Children of both sexes frequently enter central precocious puberty due to premature sex steroid exposure (see <xref ref-type="sec" rid="mccune-albright.Natural_History">Clinical Description</xref>). This typically presents with reappearance of signs of puberty in a child with previously well-controlled peripheral precocious puberty. Leuprolide therapy in combination with the above medications is an effective therapeutic strategy in most.</p>
            <p><bold>Thyroid disease.</bold> See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP09.pdf" content-type="local-data">Hyperthyroidism Management</inline-supplementary-material> (pdf). Methimazole is effective for management of hyperthyroidism. However, because FD/MAS-associated hyperthyroidism is persistent, most patients ultimately elect for definitive treatment. Thyroidectomy is the preferred definitive treatment in most affected individuals. Total gland resection is generally recommended due to the potential for thyroid tissue regrowth. Selection of an experienced high-volume endocrine surgeon is critical to minimize complications and optimize outcomes. Patients should be monitored post-surgically with yearly ultrasound examination to evaluate for tissue regrowth.</p>
            <p>Note: Radioablation is typically avoided due to potential preferential uptake by areas of mutation-bearing tissue, which may lead to increased risk of malignancy in the remaining unaffected gland. Additionally, <italic toggle="yes">GNAS</italic> mutations are associated with a slight increased risk of malignant transformation in both thyroid and non-thyroidal tissues; the risk may potentially be enhanced by radiation exposure. </p>
            <p><bold>Growth hormone (GH) excess.</bold> See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP11.pdf" content-type="local-data">GH Excess: Management</inline-supplementary-material> (pdf). Medical therapy is the preferred first-line treatment. Options include (alone or in combination) octreotide and the growth hormone receptor antagonist pegvisomant [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2013.e126">Boyce et al 2013</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.salenave.2014.1955">Salenave et al 2014</xref>].</p>
            <p>In growing children, the therapeutic goal is to maintain the IGF-1 level in the middle of the normal range with an IGF-1 Z-score of 0. </p>
            <p>In skeletally mature individuals, the goal is to decrease the IGF-1 level as low as possible. </p>
            <p>Medical therapy is typically continued indefinitely, because options for definitive treatment are associated with significant morbidity. </p>
            <p>Surgery may be technically difficult or precluded due to craniofacial FD. Additionally, given the diffuse pituitary infiltration of GH-producing cells, patients treated surgically require total hypophysectomy with resulting total hypopituitarism [<xref ref-type="bibr" rid="mccune-albright.REF.vortmeyer.2012.2404">Vortmeyer et al 2012</xref>]. </p>
            <p>Radiation treatment may be effective in refractory cases, but has been associated with fatal malignant transformation of craniofacial FD [<xref ref-type="bibr" rid="mccune-albright.REF.hansen.2003.79">Hansen &#x00026; Moffat 2003</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.liu.2011.283">Liu et al 2011</xref>].</p>
            <p>The hyperprolactinemia that frequently accompanies growth hormone excess is generally responsive to treatment with dopamine agonists, including cabergoline and bromocriptine. </p>
            <p><bold>FGF23-mediated phosphate wasting.</bold> Treatment of frank hypophosphatemia is the same as in other disorders of FGF23 excess, and includes oral phosphorus and calcitriol. Important therapeutic endpoints include growth velocity and radiographic evidence of epiphyseal healing. Unlike other disorders of FGF23 excess, bone turnover markers in FD/MAS (e.g., alkaline phosphatase) may be constitutively elevated and are not a useful indicator of skeletal response to treatment.</p>
            <p><bold>Hypercortisolism.</bold> Treatment guidelines for hypercortisolism are difficult to establish given the rarity of neonatal Cushing syndrome. Additionally patients may be critically ill at presentation, which significantly affects treatment options. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP15.pdf" content-type="local-data">Hypercortisolism Management</inline-supplementary-material> (pdf).</p>
            <p>Definitive treatment includes surgical removal of the diseased adrenal glands. </p>
            <p>For medical treatment metyrapone is frequently effective, and is preferred over ketoconazole in children with liver abnormalities.</p>
            <p>Spontaneous remission has been clearly documented in some affected individuals [<xref ref-type="bibr" rid="mccune-albright.REF.brown.2010.1508">Brown et al 2010</xref>]; however, it is not possible to identify prospectively which individuals will undergo remission. The decision to pursue or delay adrenalectomy must be made on an individual basis, taking into account the severity of illness, the ability of medications to control cortisol levels, and the potential effect of continued hypercortisolism on neurodevelopment. </p>
          </sec>
        </sec>
        <sec id="mccune-albright.Surveillance">
          <title>Surveillance</title>
          <sec id="mccune-albright.Fibrous_Dysplasia_1">
            <title>Fibrous Dysplasia</title>
            <p>Individuals with craniofacial FD should have yearly vision and hearing evaluations, and periodic computed tomography of the skull.</p>
            <p>Individuals with spine FD should be monitored closely for progressive scoliosis.</p>
            <p>Radiographs should be performed periodically to evaluate new or worsening symptoms and to provide additional information about FD anatomy and bone quality.</p>
            <p>Phosphorus levels should be checked periodically to monitor for the development of FGF23-mediated hypophosphatemia. </p>
            <p>25-hydroxyvitamin D levels should be checked periodically as part of routine bone health surveillance.</p>
          </sec>
          <sec id="mccune-albright.Endocrinopathies_1">
            <title>Endocrinopathies</title>
            <p><bold>Precocious puberty.</bold> All children should be monitored for growth acceleration and other clinical signs of precocious puberty. </p>
            <p>
              <bold>Thyroid</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Thyroid function tests should be monitored routinely in all children younger than age five years. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP08.pdf" content-type="local-data">Thyroid Evaluation</inline-supplementary-material>. </p>
              </list-item>
              <list-item>
                <p>Individuals with abnormalities on ultrasound examination but normal thyroid function tests should continue to have laboratory testing periodically throughout childhood, as the development of frank hyperthyroidism may occur later. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP08.pdf" content-type="local-data">Thyroid Evaluation</inline-supplementary-material>.</p>
              </list-item>
              <list-item>
                <p>Patients who retain abnormal thyroid tissue following thyroid surgery should be monitored with regular physical examination and periodic thyroid ultrasound examination because of the potential for thyroid tissue regrowth.</p>
              </list-item>
            </list>
            <p><bold>Testicular lesions</bold> likely have low potential for malignant transformation [<xref ref-type="bibr" rid="mccune-albright.REF.boyce.2012.e1782">Boyce et al 2012</xref>]; however, it is prudent to monitor all males with regular physical examinations and testicular ultrasound examinations. See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP07.pdf" content-type="local-data">Gonadal Involvement Management in Boys</inline-supplementary-material>.</p>
            <p><bold>Growth hormone excess.</bold> See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP10.pdf" content-type="local-data">Growth Hormone Excess Evaluation</inline-supplementary-material>: </p>
            <list list-type="bullet">
              <list-item>
                <p>All children should be monitored for growth acceleration.</p>
              </list-item>
              <list-item>
                <p>Patients treated medically with octreotide should be monitored for gallbladder disease, and with those treated with pegvisomant should be monitored for hepatotoxicity. </p>
              </list-item>
            </list>
            <p><bold>FGF23-mediated phosphate wasting.</bold> Serum phosphorus levels should be monitored routinely in all patients.</p>
            <p>
              <bold>Hypercortisolism</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Routine biochemical surveillance is not indicated; however, all infants should be monitored for clinical signs of hypercortisolism. </p>
              </list-item>
              <list-item>
                <p>Patients with a history of Cushing syndrome that has spontaneously resolved should be monitored for late-appearing adrenal insufficiency. </p>
              </list-item>
            </list>
          </sec>
          <sec id="mccune-albright.Other">
            <title>Other</title>
            <p><bold>GI.</bold> See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="mccune-albright-PP13.pdf" content-type="local-data">Gastrointestinal Management</inline-supplementary-material> (pdf).</p>
          </sec>
        </sec>
        <sec id="mccune-albright.AgentsCircumstances_to_A">
          <title>Agents/Circumstances to Avoid</title>
          <p>Contact sports and other high-risk activities should be avoided in patients with significant skeletal involvement.</p>
          <p>Prophylactic optic nerve decompression increases vision loss in patients with craniofacial FD and is contraindicated [<xref ref-type="bibr" rid="mccune-albright.REF.lee.2002.1670">Lee et al 2002</xref>, <xref ref-type="bibr" rid="mccune-albright.REF.amit.2011.e25179">Amit et al 2011</xref>].</p>
          <p>Surgical removal of ovarian cysts should be performed with caution and only in limited circumstances.</p>
          <p>Radiation therapy is not indicated for treatment of FD, and radiation exposure to FD lesions should be limited due to potential risk for malignant transformation [<xref ref-type="bibr" rid="mccune-albright.REF.ruggieri.1994.1411">Ruggieri et al 1994</xref>]. </p>
          <p>While a strong association between <italic toggle="yes">gsp</italic> mutations (i.e., activating <italic toggle="yes">GNAS</italic> mutations at residues Arg201 and Gln227) and malignancies in FD/MAS is lacking, it is prudent to minimize additional risk factors (e.g., radiation exposure) and encourage vigilance and monitoring. </p>
        </sec>
        <sec id="mccune-albright.Evaluation_of_Relatives">
          <title>Evaluation of Relatives at Risk</title>
          <p>Because FD/MAS is not inherited, relatives are not at increased risk and do not require evaluation. </p>
          <p>See <xref ref-type="sec" rid="mccune-albright.Related_Genetic_Counseli">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="mccune-albright.Pregnancy_Management">
          <title>Pregnancy Management </title>
          <p>Although the effects of pregnancy on bone and endocrine disease in women with FD/MAS are not well studied, in the authors&#x02019; experience most women do not experience a worsening of disease during pregnancy. </p>
        </sec>
        <sec id="mccune-albright.Therapies_Under_Investig">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder. </p>
        </sec>
      </sec>
      <sec id="mccune-albright.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="mccune-albright.Mode_of_Inheritance">
          <title>Mode of Inheritance </title>
          <p>Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is not inherited.</p>
          <list list-type="bullet">
            <list-item>
              <p>Verified vertical transmission has never been observed.</p>
            </list-item>
            <list-item>
              <p>Molecular data indicated that all affected individuals are mosaic for an activating <italic toggle="yes">GNAS</italic> mutation that arises sporadically early in embryonic development. </p>
            </list-item>
          </list>
        </sec>
        <sec id="mccune-albright.Risk_to_Family_Members">
          <title>Risk to Family Members </title>
          <p><bold>Parents of a proband.</bold> No parent of a child with FD/MAS has been demonstrated to have any significant, distinctive manifestations of the disorder, nor would such a finding be expected given the somatic nature of the disease.</p>
          <p><bold>Siblings of a proband.</bold> Given the somatic mutational mechanism of FD/MAS, the risk for an affected sib would be expected to be the same as in the general population.</p>
          <p><bold>Offspring of a proband.</bold> There are no verified instances of vertical transmission of FD/MAS, potentially the result of embryonic lethality.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members is the same as that in the general population.</p>
        </sec>
        <sec id="mccune-albright.Related_Genetic_Counseli">
          <title>Related Genetic Counseling Issues </title>
          <p>See Management, <xref ref-type="sec" rid="mccune-albright.Evaluation_of_Relatives">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> mosaic mutation.</bold> Counseling for recurrence risks in FD/MAS should emphasize that, while no pregnancy is at zero risk, evidence suggests that the risk of recurrence for this disorder is not increased over that of the general population.</p>
          <p><bold>Family planning.</bold> It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="mccune-albright.Prenatal_Testing">
          <title>Prenatal Testing </title>
          <p><bold>Molecular genetic testing.</bold> As FD/MAS is mosaic and not inherited, prenatal testing is not indicated.</p>
        </sec>
      </sec>
      <sec id="mccune-albright.Resources">
        <title>Resources</title>
      </sec>
      <sec id="mccune-albright.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="mccune-albright.Molecular_Genetic_Pathog">
          <title>Molecular Genetic Pathogenesis </title>
          <p>Activating or gain-of-function <italic toggle="yes">GNAS</italic> mutations in individuals with FD/MAS are present in the mosaic state, resulting from a postzygotic somatic mutation appearing early in the course of development which yields a monoclonal population of mutated cells within variously affected tissues. The non-mosaic state for most activating mutations is presumably lethal to the embryo (modified from OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/174800">174800</ext-link>).</p>
          <p><italic toggle="yes">GNAS</italic> encodes the cAMP pathway-associated G-protein, G<sub>s</sub>&#x003b1;. Mutation of specific amino acid residues result in dysregulation and constitutive activation of signal transduction pathways generating cAMP. </p>
          <p>The spectrum of FD/MAS ranges from asymptomatic incidental findings to neonatal lethality. The phenotype of FD/MAS is a reflection of the role of G<sub>s</sub>&#x003b1; in that tissue and whether or not a given tissue harbors a mutation in <italic toggle="yes">GNAS</italic>. The distribution of affected tissues is a reflection of the timing of the occurrence of the sporadic mutation during development and the fate of the specific clone in which the mutation occurs. It is likely that the stem cells of certain tissues will not tolerate mutant G<sub>s</sub>&#x003b1; and are eliminated during development. Therefore, some tissues in which there is significant G<sub>s</sub>&#x003b1; signaling will not be affected. For example, G<sub>s</sub>&#x003b1; signaling is important in growth plate development, yet the growth plate is virtually never affected. </p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">GNAS</italic> is a complex locus with an imprinted expression pattern. Multiple gene products, including maternally, paternally, and biallelically expressed transcripts, are derived from the use of four promoters and 5&#x02019; exons that splice onto a common set of downstream exons [<xref ref-type="bibr" rid="mccune-albright.REF.weinstein.2004.5459">Weinstein et al 2004</xref>] (summarized in OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/139320">139320</ext-link>). The major <italic toggle="yes">GNAS</italic> product is the ubiquitously expressed G<sub>s</sub>&#x003b1;, which is generated by the most downstream promoter (exon 1). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="mccune-albright" object-id="mccune-albright.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> Somatic mosaicism for the missense pathogenic variants resulting in amino acid substitution at the Arg201 position have been identified in more than 95% of all published reports of FD/MAS. The mutation is nearly always a substitution of the residue arginine at position 201 by histidine (His) or cysteine (Cys) [<xref ref-type="bibr" rid="mccune-albright.REF.lumbroso.2004.2107">Lumbroso et al 2004</xref>]. Very infrequently, arginine is replaced by serine, glycine, or leucine. Rarely, mutation of the Gln227 residue to Arg is found [<xref ref-type="bibr" rid="mccune-albright.REF.idowu.2007.691">Idowu et al 2007</xref>]. </p>
          <table-wrap id="mccune-albright.T.gnas_somatic_variants" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p><italic toggle="yes">GNAS</italic> Somatic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.601C&#x0003e;T</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201Cys</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_3" rowspan="9" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000516.4">NM_000516.4</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000507.1">NP_000507.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.601C&#x0003e;G</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201Gly</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.601C&#x0003e;A</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.602G&#x0003e;A</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201His</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.602G&#x0003e;T</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg201Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.679C&#x0003e;A</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln227Lys</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.680A&#x0003e;T</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln227Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.680A&#x0003e;G</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln227Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.681G&#x0003e;T</td>
                  <td headers="hd_h_mccune-albright.T.gnas_somatic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln227His</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> G<sub>s</sub>&#x003b1; is a key component of many hormonal and other signal transduction pathways. Its primary role is to couple G-coupled protein receptors to adenylyl cyclase, promoting receptor-stimulated production of intracellular cAMP. G<sub>s</sub>&#x003b1; in its inactive state forms a heterotrimer with the G<sub>s</sub>&#x003b2; and G<sub>s</sub>&#x003b3; subunits, with GDP bound to its binding site. Ligand binding to the G-coupled protein receptor promotes release of GDP from the &#x003b1;-subunit and binding of GTP. The GTP-bound G<sub>s</sub>&#x003b1; dissociates from the &#x003b2;-&#x003b3; heterotrimer and translocates to interact with adenylyl cyclase to promote cAMP production. Intrinsic GTPase hydrolyzes the bound GTP to GDP, leading to cessation of cAMP generation and reassembly of the &#x003b1;-&#x003b2;-&#x003b3; heterotrimer.</p>
          <p><bold>Abnormal gene product.</bold> The FD/MAS-associated <italic toggle="yes">GNAS</italic> variants at residues Arg201 and Gln227 disrupt the activity of intrinsic GTPase, causing constitutive activity and inappropriately increased cAMP signaling [<xref ref-type="bibr" rid="mccune-albright.REF.landis.1989.692">Landis et al 1989</xref>].</p>
        </sec>
      </sec>
      <sec id="mccune-albright.References">
        <title>References</title>
        <sec id="mccune-albright.Literature_Cited">
          <title>Literature Cited </title>
          <ref-list id="mccune-albright.Literature_Cited.reflist0">
            <ref id="mccune-albright.REF.amit.2011.e25179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amit</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>FitzGibbon</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butman</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fliss</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gil</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <article-title>Surgery versus watchful waiting in patients with craniofacial fibrous dysplasia--a meta-analysis.</article-title>
                <source>PLoS One.</source>
                <year>2011</year>
                <volume>6</volume>
                <fpage>e25179</fpage>
                <pub-id pub-id-type="pmid">21966448</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.bhattacharyya.2012.1132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bhattacharyya</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiench</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumitrescu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bugge</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>HV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gafni</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hager</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Mechanism of FGF23 processing in fibrous dysplasia.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2012</year>
                <volume>27</volume>
                <fpage>1132</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">22247037</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.bianco.2000.120">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riminucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majolagbe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuznetsov</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mankani</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corsi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bone</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiegel</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                </person-group>
                <article-title>Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2000</year>
                <volume>15</volume>
                <fpage>120</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10646121</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.boyce.2012.e1782">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyce</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shawker</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinto</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linehan</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhattacharryya</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merino</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singer</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Characterization and management of testicular pathology in McCune-Albright syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2012</year>
                <volume>97</volume>
                <fpage>E1782</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">22745241</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.boyce.2012">
              <mixed-citation publication-type="other">Boyce AM, Collins MT. <italic toggle="yes">Diagnosis and Clinical Management in Fibrous Dysplasia/McCune-Albright Syndrome</italic>. PowerPoint slide presentation. 2012.</mixed-citation>
            </ref>
            <ref id="mccune-albright.REF.boyce.2013.e126">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyce</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glover</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butman</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgibbon</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brewer</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zalewski</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutler Peck</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2013</year>
                <volume>98</volume>
                <fpage>E126</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">23093488</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.boyce.2014.4133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyce</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riminucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2014</year>
                <volume>99</volume>
                <fpage>4133</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">25033066</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.brown.2010.1508">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Cushing syndrome in the McCune-Albright syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2010</year>
                <volume>95</volume>
                <fpage>1508</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">20157193</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.carney.2011.1311">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carney</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratakis</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune-Albright syndrome.</article-title>
                <source>Am J Surg Pathol.</source>
                <year>2011</year>
                <volume>35</volume>
                <fpage>1311</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">21836496</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.celi.2008.2383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Celi</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coppotelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chidakel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shawker</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuillan</surname>
                    <given-names>PP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2008</year>
                <volume>93</volume>
                <fpage>2383</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18349068</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.clark.2000.204">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennedy</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <article-title>Asynchronous ovarian torsion in a patient with McCune-Albright syndrome.</article-title>
                <source>J Obstet Gynaecol.</source>
                <year>2000</year>
                <volume>20</volume>
                <fpage>204</fpage>
                <pub-id pub-id-type="pmid">15512529</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.collins.2001.806">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chebli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Consugar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                </person-group>
                <article-title>Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2001</year>
                <volume>16</volume>
                <fpage>806</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">11341325</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.collins.2005.219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynolds</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chebli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leet</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riminucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CC</given-names>
                  </name>
                </person-group>
                <article-title>An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2005</year>
                <volume>20</volume>
                <fpage>219</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">15647815</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.collins.2003.4413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarlis</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merino</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monroe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krakoff</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guthrie</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonat</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenker</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2003</year>
                <volume>88</volume>
                <fpage>4413</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12970318</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.cutler.2006.1011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cutler</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butman</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>FitzGibbon</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuillan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DuFresne</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation.</article-title>
                <source>Neurosurgery.</source>
                <year>2006</year>
                <volume>59</volume>
                <fpage>1011</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17143235</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.davies.1993.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>HE</given-names>
                  </name>
                </person-group>
                <article-title>Imprinting in Albright's hereditary osteodystrophy.</article-title>
                <source>J Med Genet.</source>
                <year>1993</year>
                <volume>30</volume>
                <fpage>101</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">8383205</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.eugster.2003.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eugster</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubin</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reiter</surname>
                    <given-names>EO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plourde</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jou</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pescovitz</surname>
                    <given-names>OH</given-names>
                  </name>
                </person-group>
                <article-title>McCune-Albright Study Group. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial.</article-title>
                <source>J Pediatr.</source>
                <year>2003</year>
                <volume>143</volume>
                <fpage>60</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12915825</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.feuillan.2007.2100">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feuillan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calis</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hill</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shawker</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>2100</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17405850</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.gaujoux.2014.e97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gaujoux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salenave</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rangheard</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cros</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belghiti</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauvanet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruszniewski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Hepatobiliary and Pancreatic neoplasms in patients with McCune-Albright syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2014</year>
                <volume>99</volume>
                <fpage>E97</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">24170100</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.hansen.2003.79">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moffat</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <article-title>Osteosarcoma of the skull base after radiation therapy in a patient with McCune-Albright syndrome: case report.</article-title>
                <source>Skull Base.</source>
                <year>2003</year>
                <volume>13</volume>
                <fpage>79</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">15912163</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.hart.2007.1468">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ziran</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuillan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leet</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2007</year>
                <volume>22</volume>
                <fpage>1468</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">17501668</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.idowu.2007.691">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Idowu</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Adnani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donnell</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odell</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diss</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gale</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone.</article-title>
                <source>Histopathology.</source>
                <year>2007</year>
                <volume>50</volume>
                <fpage>691</fpage>
                <lpage>704</lpage>
                <pub-id pub-id-type="pmid">17493233</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.j_ppner.1998.11798">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>J&#x000fc;ppner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schipani</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastepe</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannstadt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendy</surname>
                    <given-names>GN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plotkin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koshiyama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olsen</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>The gene responsible for pseudohypoparathyroidism type Ib is paternally imprinted and maps in four unrelated kindreds to chromosome 20q13.3.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>1998</year>
                <volume>95</volume>
                <fpage>11798</fpage>
                <lpage>803</lpage>
                <pub-id pub-id-type="pmid">9751745</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.kelly.2008.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions.</article-title>
                <source>Osteoporos Int.</source>
                <year>2008</year>
                <volume>19</volume>
                <fpage>57</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">17622477</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.kelly.2005.388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gehron Robey</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Physical function is impaired but quality of life preserved in patients with fibrous dysplasia of bone.</article-title>
                <source>Bone.</source>
                <year>2005</year>
                <volume>37</volume>
                <fpage>388</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">15963775</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.kuznetsov.2008.1731">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuznetsov</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riminucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Age-dependent demise of GNAS-mutated skeletal stem cells and "normalization" of fibrous dysplasia of bone.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2008</year>
                <volume>23</volume>
                <fpage>1731</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">18597624</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.lala.2007.423">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lala</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andreo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pucci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matarazzo</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Persistent hyperestrogenism after precocious puberty in young females with McCune-Albright syndrome.</article-title>
                <source>Pediatr Endocrinol Rev.</source>
                <year>2007</year>
                <volume>4</volume>
                <supplement>Suppl 4</supplement>
                <fpage>423</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17982390</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.landis.1989.692">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Landis</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masters</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pace</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourne</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallar</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.</article-title>
                <source>Nature.</source>
                <year>1989</year>
                <volume>340</volume>
                <fpage>692</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">2549426</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.lawless.1992.1099">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lawless</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reeves</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowen</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>The development of thyroid storm in a child with McCune-Albright syndrome after orthopedic surgery.</article-title>
                <source>Am J Dis Child.</source>
                <year>1992</year>
                <volume>146</volume>
                <fpage>1099</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">1514560</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.lee.2012.s2">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>FitzGibbon</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lustig</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akintoye</surname>
                    <given-names>SO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaban</surname>
                    <given-names>LB</given-names>
                  </name>
                </person-group>
                <article-title>Clinical guidelines for the management of craniofacial fibrous dysplasia.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2012</year>
                <volume>7</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S2</fpage>
                <pub-id pub-id-type="pmid">22640797</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.lee.2002.1670">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>FitzGibbon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butman</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufresne</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Normal vision despite narrowing of the optic canal in fibrous dysplasia.</article-title>
                <source>N Engl J Med.</source>
                <year>2002</year>
                <volume>347</volume>
                <fpage>1670</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12444181</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.leet.2004a.571">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leet</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chebli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brillante</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.</article-title>
                <source>J Bone Miner Res.</source>
                <year>2004a</year>
                <volume>19</volume>
                <fpage>571</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15005844</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.leet.2004b.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leet</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magur</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robey</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis.</article-title>
                <source>J Bone Joint Surg Am.</source>
                <year>2004b</year>
                <volume>86-A</volume>
                <issue>3</issue>
                <fpage>531</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14996879</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.levine.2012.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>An update on the clinical and molecular characteristics of pseudohypoparathyroidism.</article-title>
                <source>Curr Opin Endocrinol Diabetes Obes.</source>
                <year>2012</year>
                <volume>19</volume>
                <fpage>443</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">23076042</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.lim.2014.397">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ovejero</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugarman</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deklotz</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruri</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichenfield</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>PK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000fc;ppner</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gottschalk</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tifft</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gafni</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyce</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowen</surname>
                    <given-names>EW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhattacharyya</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guthrie</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gahl</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loring</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Overton</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mane</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lifton</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choate</surname>
                    <given-names>KA</given-names>
                  </name>
                </person-group>
                <article-title>Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2014</year>
                <volume>23</volume>
                <fpage>397</fpage>
                <lpage>407</lpage>
                <pub-id pub-id-type="pmid">24006476</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.liu.2011.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dou</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhong</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>A case of McCune-Albright syndrome associated with pituitary GH adenoma: therapeutic process and autopsy.</article-title>
                <source>J Pediatr Endocrinol Metab.</source>
                <year>2011</year>
                <volume>24</volume>
                <fpage>283</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21823524</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.lumbroso.2004.2107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lumbroso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paris</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sultan</surname>
                    <given-names>C</given-names>
                  </name>
                  <collab>European Collaborative Study</collab>
                </person-group>
                <article-title>Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2004</year>
                <volume>89</volume>
                <fpage>2107</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">15126527</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.mancini.2009.196">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corsi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Maio</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riminucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ippolito</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Scoliosis and spine involvement in fibrous dysplasia of bone.</article-title>
                <source>Eur Spine J.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>196</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">19130098</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.manjila.2013">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manjila</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zender</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weaver</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodgers</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <article-title>Aneurysmal bone cyst within fibrous dysplasia of the anterior skull base: continued intracranial extension after endoscopic resections requiring craniofacial approach with free tissue transfer reconstruction.</article-title>
                <source>Childs Nerv Syst.</source>
                <year>2013</year>
                <month>Feb</month>
                <day>26</day>
                <comment>Epub ahead of print</comment>
                <pub-id pub-id-type="pmid">23435492</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.mantovani.2011.3020">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mantovani</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Clinical review: Pseudohypoparathyroidism: diagnosis and treatment.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2011</year>
                <month>Oct</month>
                <volume>96</volume>
                <issue>10</issue>
                <fpage>3020</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">21816789</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.narumi.2013.e60525">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Narumi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Quantitative and sensitive detection of GNAS mutations causing mccune-albright syndrome with next generation sequencing.</article-title>
                <source>PLoS One.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>e60525</fpage>
                <pub-id pub-id-type="pmid">23536913</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.paul.2014.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabor</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudzinski</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovanni</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyce</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia.</article-title>
                <source>Bone.</source>
                <year>2014</year>
                <volume>60</volume>
                <fpage>41</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">24316419</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.pignolo.2015.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pignolo</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswamy</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shore</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>FS</given-names>
                  </name>
                </person-group>
                <article-title>Progressive osseous heteroplasia: diagnosis, treatment, and prognosis.</article-title>
                <source>Appl Clin Genet.</source>
                <year>2015</year>
                <volume>8</volume>
                <fpage>37</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">25674011</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.riminucci.2003.683">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Riminucci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fedarko</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corsi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waguespack</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannon</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Econs</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bianco</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gehron Robey</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.</article-title>
                <source>J Clin Invest.</source>
                <year>2003</year>
                <volume>112</volume>
                <fpage>683</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">12952917</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.ruggieri.1994.1411">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruggieri</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sim</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bond</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unni</surname>
                    <given-names>KK</given-names>
                  </name>
                </person-group>
                <article-title>Malignancies in fibrous dysplasia.</article-title>
                <source>Cancer.</source>
                <year>1994</year>
                <volume>73</volume>
                <fpage>1411</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">8111708</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.salenave.2014.1955">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salenave</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boyce</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanson</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Acromegaly and McCune-Albright syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2014</year>
                <volume>99</volume>
                <fpage>1955</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">24517150</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.shore.2002.99">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shore</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahn</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jan de Beur</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zasloff</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whyte</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>FS</given-names>
                  </name>
                </person-group>
                <article-title>Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia.</article-title>
                <source>N Engl J Med.</source>
                <year>2002</year>
                <volume>346</volume>
                <fpage>99</fpage>
                <lpage>106</lpage>
                <pub-id pub-id-type="pmid">11784876</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.silva.2000.154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lumbroso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Medina</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillerot</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sultan</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sokal</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <article-title>Demonstration of McCune-Albright mutations in the liver of children with high gammaGT progressive cholestasis.</article-title>
                <source>J Hepatol.</source>
                <year>2000</year>
                <volume>32</volume>
                <fpage>154</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10673080</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.stanton.2012.s1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stanton</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ippolito</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Springfield</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindaman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wientroub</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leet</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>The surgical management of fibrous dysplasia of bone.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2012</year>
                <volume>7</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S1</fpage>
                <pub-id pub-id-type="pmid">22640754</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.tanabeu.1998.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tanabeu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakahara</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitsuyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ono</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toyoshima</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Breast cancer in a patient with McCune-Albright syndrome.</article-title>
                <source>Breast Cancer.</source>
                <year>1998</year>
                <volume>5</volume>
                <fpage>175</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11091644</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.vortmeyer.2012.2404">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vortmeyer</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gl&#x000e4;sker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>GU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abu-Asab</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhuang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldfield</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <article-title>Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <year>2012</year>
                <volume>97</volume>
                <fpage>2404</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">22564667</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.weinstein.1990.8287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gejman</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadowaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gershon</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiegel</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>Mutations of the Gs alpha-subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>1990</year>
                <volume>87</volume>
                <fpage>8287</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">2122458</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.weinstein.2004.5459">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Minireview: GNAS: normal and abnormal functions.</article-title>
                <source>Endocrinology.</source>
                <year>2004</year>
                <volume>145</volume>
                <fpage>5459</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">15331575</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.wood.2007.1108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sj&#x000f6;blom</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leary</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boca</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barber</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ptak</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silliman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szabo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dezso</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ustyanksky</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikolskaya</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikolsky</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karchin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaminker</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Croshaw</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dawson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shipitsin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willson</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sukumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polyak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pethiyagoda</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pant</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballinger</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sparks</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartigan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suh</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papadopoulos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckhaults</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markowitz</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parmigiani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinzler</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Velculescu</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogelstein</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>The genomic landscapes of human breast and colorectal cancers.</article-title>
                <source>Science.</source>
                <year>2007</year>
                <volume>318</volume>
                <fpage>1108</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">17932254</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.zacharin.2011.458">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zacharin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bajpai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chow</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catto-Smith</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratakis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Gastrointestinal polyps in McCune Albright syndrome.</article-title>
                <source>J Med Genet.</source>
                <year>2011</year>
                <volume>48</volume>
                <fpage>458</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">21357941</pub-id>
              </element-citation>
            </ref>
            <ref id="mccune-albright.REF.zoccali.2009.605">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zoccali</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teori</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prencipe</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erba</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Mazabraud's syndrome: a new case and review of the literature.</article-title>
                <source>Int Orthop.</source>
                <year>2009</year>
                <volume>33</volume>
                <fpage>605</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">18214477</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="mccune-albright.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="mccune-albright.Author_Notes">
          <title>Author Notes </title>
          <p>Alison M Boyce, MD is a pediatric endocrinologist who specializes in the evaluation and treatment of bone disorders in children and adolescents. She performs clinical research in FD/MAS and other pediatric skeletal diseases at the National Institutes of Health and Children&#x02019;s National Medical Center.</p>
          <p>Michael T Collins, MD is an endocrinologist who conducts translation research at the National Institutes of Health. He studies and treats patients with primarily rare disorders of bone and mineral homeostasis, including FD/MAS.</p>
        </sec>
        <sec id="mccune-albright.Acknowledgments">
          <title>Acknowledgments</title>
          <p>This research was supported by the Intramural Research Program of the NIH, NIDCR (AMB, MTC) and the Bone Health Program, Division of Orthopaedics and Sports Medicine, Children&#x02019;s National Health System (AMB). The authors are grateful to the patients and their families for participation in the research and the efforts of the trainees of the NIH Interinstitute Endocrine Training Program for the excellent care they provide to our research subjects at the NIH Mark O. Hatfield Clinical Research Center. </p>
        </sec>
        <sec id="mccune-albright.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>26 February 2015 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>17 October 2014 (amb) Original submission</p>
            </list-item>
          </list>
          <p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <italic toggle="yes">GeneReview</italic> &#x02018;Fibrous Dysplasia/McCune-Albright Syndrome&#x02019; is in the public domain in the United States of America.</p>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="mccune-albright.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Caf&#x000e9;-au-lait skin pigmentationA. Skin lesions in a newborn demonstrating the characteristic association with the midline of the body, and distribution reflecting patterns of embryonic cell migration (developmental lines of Blaschko)B. A typical lesion on the chest, face, and arm demonstrating the irregular &#x0201c;coast of Maine&#x0201d; borders, relationship with the midline of the body, and distribution following developmental lines of BlaschkoC. Typical lesions frequently found on the nape of the neck and crease of the buttocks</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mccune-albright-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="mccune-albright.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Fibrous dysplasia (FD)A. Proximal femur FD demonstrating the typical ground glass appearance with a coxa vara (&#x0201c;shepherd&#x02019;s crook&#x0201d;) deformityB. Three-dimensional reconstructed computed tomography (CT) image of a man age 26 years with craniofacial FD and uncontrolled growth hormone excess, leading to macrocephaly and severe facial deformityC. CT image from a girl age ten years demonstrating the typical ground glass appearance of craniofacial FD in younger individuals. The optic canals are typically encased in FD (white arrows) without any visual disturbance. D. CT image from a woman age 40 years demonstrating typical features of craniofacial FD in an older individual, including a more sclerotic appearance with mixed solid and cystic components. Again depicted are the optic nerves encased in FD (white arrows) without visual disturbance.E. <sup>99</sup>Technetium bone scintigraphy, posterior-anterior and anterior-posterior views, left and right panels, respectively demonstrating patchy tracer uptake at affected skeletal sites, including the skull, spine, and foot (arrows), consistent with a mosaic pattern of expression</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mccune-albright-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="mccune-albright.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>UltrasonographyA. Pelvic ultrasound in a girl age seven years showing a complex unilateral ovarian cyst (defined by cross-hatches). The uterus is prepubertal in size (arrow). B. Testicular ultrasound in an adult showing a heterogeneous lesion with mixed solid and cystic elementsC&#x00026;D. Typical thyroid ultrasound findings, including heterogeneity and a cystic (&#x0201c;Swiss cheese&#x0201d;) appearance</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mccune-albright-Image003" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
